Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Study of OCT Peripapillary Angiography in Patients With Advanced Glaucoma

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Glaucoma is a chronic disease of the optic nerve, characterized by progressive loss of nerve cells in the retina, leading to progressive loss of peripheral and central vision. There are in fact several types of glaucoma, which is the world's second leading cause of blindness after cataracts, and the leading cause of irreversible blindness. To date, to our knowledge, there is no work analyzing the progression of angiographic OCT in patients with glaucoma. The main aim of this study is to compare the 3-year progression rate of 3 examinations in advanced glaucoma patients: one functional (visual field) and two anatomical (OCTa and OCTrnfl).

Who May Be Eligible (Plain English)

Who May Qualify: - Men and women aged 18 and over - Patient with glaucoma followed in the ophthalmology department of Nantes University Hospital - mean visual field deficit (MD) \>10dB Who Should NOT Join This Trial: - Retinal vascular pathology (moderate to severe non-proliferative diabetic retinopathy, complicated diabetic retinopathy, OVCR/OBVR, OACR/OBAR, NOIAA...) Non-glaucomatous optic neuropathy, neurological pathology leading to visual field deficit (stroke with HLH, quadranopsia, chiasmatic Sd...) - PPR (retinal PanPhotocoagulation), retinal cerclage - Retinal pathology leading to visual field impairment (e.g. retinitis pigmentosa) - AMD and other macular pathologies that can lead to central visual field deficits - Significant environmental disorders impairing retinal imaging (e.g. active uveitis, dense cataract) - Loss of fixation point preventing visual field formation Pregnant or breast-feeding women - Protected adults under guardianship or curatorship - with unreliable visual fields (false positives and false negatives \> 33%) - with an uninterpretable OCTrnfl or OCTa (artifact, low quality score) Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Men and women aged 18 and over * Patient with glaucoma followed in the ophthalmology department of Nantes University Hospital * mean visual field deficit (MD) \>10dB Exclusion Criteria: * Retinal vascular pathology (moderate to severe non-proliferative diabetic retinopathy, complicated diabetic retinopathy, OVCR/OBVR, OACR/OBAR, NOIAA...) Non-glaucomatous optic neuropathy, neurological pathology leading to visual field deficit (stroke with HLH, quadranopsia, chiasmatic Sd...) * PPR (retinal PanPhotocoagulation), retinal cerclage * Retinal pathology leading to visual field impairment (e.g. retinitis pigmentosa) * AMD and other macular pathologies that can lead to central visual field deficits * Significant environmental disorders impairing retinal imaging (e.g. active uveitis, dense cataract) * Loss of fixation point preventing visual field formation Pregnant or breast-feeding women * Protected adults under guardianship or curatorship * with unreliable visual fields (false positives and false negatives \> 33%) * with an uninterpretable OCTrnfl or OCTa (artifact, low quality score)

Treatments Being Tested

DEVICE

OCT

Peripapillary angiography (OCT) at baseline and each year during 3 year

Locations (2)

CHU Nantes
Nantes, France
Jean-Baptiste Ducloyer
Nantes, France